M. Carlsson, E. Berntorp, S. Björkman, and K. Lindvall, Pharmacokinetic dosing in prophylactic treatment of hemophilia A, European Journal of Haematology, vol.13, issue.suppl 30, pp.247-252, 1993.
DOI : 10.1111/j.1600-0609.1993.tb00638.x

M. Carlsson, E. Berntorp, S. Björkman, S. Lethagen, and R. Ljung, Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A, Haemophilia, vol.3, issue.2, pp.96-101, 1997.
DOI : 10.1046/j.1365-2516.1997.00091.x

S. Björkman and E. Berntorp, Pharmacokinetics of Coagulation Factors, Clinical Pharmacokinetics, vol.344, issue.11, pp.815-832, 2001.
DOI : 10.2165/00003088-200140110-00003

S. Björkman, Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective, Haemophilia, vol.46, issue.s1, pp.101-110, 2003.
DOI : 10.1046/j.1365-2141.1996.d01-1705.x

A. Shapiro, J. Korth-bradley, and M. Poon, Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia, Haemophilia, vol.104, issue.2, pp.571-582, 2005.
DOI : 10.1046/j.1365-2516.2003.00721.x

A. Aronstam, D. Mclellan, M. Wassef, and P. Mbhata, Effect of height and weight on the in vivo recovery of transfused factor VIII C., Journal of Clinical Pathology, vol.35, issue.3, pp.289-291, 1982.
DOI : 10.1136/jcp.35.3.289

M. Matucci, A. Messori, G. Donati-cori, G. Longo, S. Vannini et al., Kinetic evaluation of four Factor VIII concentrates by model-independent methods, Scandinavian Journal of Haematology, vol.26, issue.Suppl, pp.22-28, 1985.
DOI : 10.1111/j.1600-0609.1985.tb00739.x

K. Fijnvandraat, M. Peters, and J. Cate, Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels, British Journal of Haematology, vol.70, issue.2, pp.474-476, 1995.
DOI : 10.1007/BF00637604

A. Vlot, E. Mauser-bunschoten, A. Zarkova, E. Haan, C. Kruitwagen et al., The half-life of infused factor VIII is shorter in hemophiliac patients with blood group 0 than in those with blood group A, Thromb Haemost, vol.83, pp.65-69, 2002.

K. Van-dijk, J. Van-der-bom, P. Lenting, P. De-groot, E. Mauser-bunschoten et al., Factor VIII half-life and clinical phenotype of severe hemophilia A, Haematologica, vol.90, pp.494-498, 2005.

C. Barnes, D. Lillicrap, J. Pazmino-canizares, V. Blanchette, A. Stain et al., ) in children and causes of inter-patient pharmacokinetic variability, Haemophilia, vol.257, issue.1, pp.40-49, 2006.
DOI : 10.1016/S0955-3886(98)00024-1

H. Stass, Determination of minimal sampling time points for reliable pharmacokinetic evaluation of recombinant factor VIII ? an exploratory population pharmacokinetic analysis in paediatric patients suffering from severe haemophilia, Haemophilia, vol.40, issue.s4, pp.50-55, 2006.
DOI : 10.2165/00003088-200140110-00003

S. Björkman, A. Folkesson, and E. Berntorp, In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting, Haemophilia, vol.87, issue.40, pp.2-8, 2007.
DOI : 10.1046/j.1365-2516.9.s1.4.x

V. Blanchette, A. Shapiro, R. Liesner, H. Navarro, F. Warrier et al., Plasma and albumin-free recombinant factorVIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients, Journal of Thrombosis and Haemostasis, vol.3, issue.8, pp.1319-1326, 2008.
DOI : 10.1111/j.1538-7836.2008.03032.x

L. Aarons, Population pharmacokinetics: theory and practice, Br J Clin Pharmacol, vol.32, pp.669-670, 1991.

M. Karlsson and L. Sheiner, The importance of modeling interoccasion variability in population pharmacokinetic analyses, Journal of Pharmacokinetics and Biopharmaceutics, vol.32, issue.6, pp.735-750, 1993.
DOI : 10.1007/BF01113502

S. Björkman, M. Carlsson, E. Berntorp, and P. Stenberg, Pharmacokinetics of Factor VIII in Humans, Clinical Pharmacokinetics, vol.22, issue.5, pp.385-395, 1992.
DOI : 10.2165/00003088-199222050-00005

J. Ahnström, E. Berntorp, K. Lindvall, and S. Björkman, A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia, Haemophilia, vol.23, issue.2, pp.689-697, 2004.
DOI : 10.1111/j.1538-7836.2004.00528.x

S. Rosén, Assay of Factor VIII:C with a Chromogenic Substrate, Scandinavian Journal of Haematology, vol.70, issue.S40, pp.139-145, 1984.
DOI : 10.1111/j.1600-0609.1984.tb02556.x

S. Beal and L. Sheiner, ) NONMEM users guides, Icon Development Solutions, 1989.

B. Meibohm, S. Läer, J. Panetta, and J. Barrett, Population pharmacokinetic studies in pediatrics: Issues in design and analysis, The AAPS Journal, vol.7, issue.2, pp.475-487, 2005.
DOI : 10.1208/aapsj070248

E. Jonsson and M. Karlsson, Xpose???an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM, Computer Methods and Programs in Biomedicine, vol.58, issue.1, pp.51-64, 1999.
DOI : 10.1016/S0169-2607(98)00067-4

J. Mandema, D. Verotta, and L. Sheiner, Building population pharmacokineticpharmacodynamic models. I. Models for covariate effects, Journal of Pharmacokinetics and Biopharmaceutics, vol.19, issue.5, pp.511-528, 1992.
DOI : 10.1007/BF01061469

E. Jonsson and M. Karlsson, Automated covariate model building within NONMEM, Pharmaceutical Research, vol.15, issue.9, pp.1463-1468, 1998.
DOI : 10.1023/A:1011970125687

L. Sheiner, S. Beal, B. Rosenberg, and V. Marathe, Forecasting individual pharmacokinetics, Clinical Pharmacology & Therapeutics, vol.26, issue.3, pp.294-305, 1979.
DOI : 10.1002/cpt1979263294

R. Savic, J. Wilkins, and M. Karlsson, )informativeness of empirical Bayes estimate-based diagnostics, AAPS J, vol.8, 2006.

M. Karlsson and R. Savic, Diagnosing Model Diagnostics, Clinical Pharmacology & Therapeutics, vol.23, issue.1, pp.17-20, 2007.
DOI : 10.1038/sj.clpt.6100241

M. Bolon-larger, V. Chamouard, F. Bressolle, and R. Boulieu, A Limited Sampling Strategy for Estimating Individual Pharmacokinetic Parameters of Coagulation Factor VIII in Patients With Hemophilia A, Therapeutic Drug Monitoring, vol.29, issue.1, pp.20-26, 2007.
DOI : 10.1097/FTD.0b013e3180311384

S. Björkman and M. Carlsson, The pharmacokinetics of factor VIII and factor IX: methodology, pitfalls and applications, Haemophilia, vol.3, issue.1, pp.1-8, 1997.
DOI : 10.1046/j.1365-2516.1997.00074.x

A. Messori, G. Longo, M. Matucci, M. Morfini, R. Ferrini et al., Clinical Pharmacokinetics of Factor VIII in Patients with Classic Haemophilia, Clinical Pharmacokinetics, vol.13, issue.6, pp.365-380, 1987.
DOI : 10.2165/00003088-198713060-00002

N. Holford, A Size Standard for Pharmacokinetics, Clinical Pharmacokinetics, vol.30, issue.5, pp.329-332, 1996.
DOI : 10.2165/00003088-199630050-00001

R. Schwartz, C. Abildgaard, L. Aledort, S. Arkin, A. Bloom et al., Human Recombinant DNA???Derived Antihemophilic Factor (Factor VIII) in the Treatment of Hemophilia A, New England Journal of Medicine, vol.323, issue.26, pp.1800-1805, 1990.
DOI : 10.1056/NEJM199012273232604

J. Harrison, A. Bloom, and C. Abildgaard, The pharmacokinetics of recombinant factor VIII, Semin Hematol, vol.28, pp.29-35, 1991.

M. Morfini, G. Longo, A. Messori, M. Lee, G. White et al., Pharmacokinetic properties of recombinant factor VIII compared with a monoclonally purified concentrate (Hemofil® M), Thrombos Haemostas, vol.68, pp.433-435, 1992.

G. White, S. Courter, G. Bray, M. Lee, and E. Gomperts, A multicenter study of recombinant factor VIII (Recombinate?) in previously treated patients with hemophilia A, Thrombos Haemostas, vol.77, pp.660-667, 1997.

K. Fischer, J. Astermark, J. Van-der-bom, R. Ljung, E. Berntorp et al., Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen, Haemophilia, vol.43, issue.6, pp.753-760, 2002.
DOI : 10.1046/j.1365-2516.2000.00383.x

P. Collins, V. Blanchette, K. Fischer, S. Björkman, M. Oh et al., Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A, Journal of Thrombosis and Haemostasis, vol.10, issue.Suppl. 4, pp.413-420, 2009.
DOI : 10.1111/j.1538-7836.2008.03270.x